EAM Investors’s Apogee Therapeutics APGE Stock Holding History

EAM Investors’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-55,113	Closed	-$3.66M	–	251
2024 Q1	$3.66M	Buy	+55,113	New	+$2.41M	0.57%	91

Other funds holding APGE

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EAM Investors's APGE Position: Q2 2024 in Review

EAM Investors sold out of Apogee Therapeutics (APGE) in Q2 2024, closing a stake of 55,113 shares — an estimated $3.66M sold.

EAM Investors first reported a position in APGE in Q1 2024 and held it in 1 quarter. The position peaked at $3.66M in Q1 2024. 139 funds tracked by Wall St. Rank hold APGE as of Q2 2024.

EAM Investors reported no remaining Apogee Therapeutics position as of Q2 2024 after selling out during the quarter.
EAM Investors sold 55,113 Apogee Therapeutics shares in Q2 2024, an estimated $3.66M.
EAM Investors first reported a position in Apogee Therapeutics in Q1 2024 and held it in 1 quarter.
EAM Investors's Apogee Therapeutics position peaked at $3.66M in Q1 2024.
139 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2024.

Based on EAM Investors's 13F filing for Q2 2024, filed 12 Aug 2024.